Search clinical trials for: MK-4621

Total 1765 results

Merck Sharp & Dohme LLC

Terminated

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Advanced Solid Tumors

Germany, Spain, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Advanced Solid Tumors

France, Germany, Spain, United Kingdom
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Thallion Pharmaceuticals

Completed

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

Glioma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Tumors

Canada
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Glioblastoma Multiforme

United States, Canada
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Food Effect and Mass Balance Study of XZP-3621 Tablets

Healthy

China
Bayer

Completed

To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Neoplasms

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
NeurAxon Inc.

Completed

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Post Herpetic Neuralgia

United States, Canada
CalciMedica, Inc.

Active, not recruiting

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (CARPO)

Systemic Inflammatory Response Syndrome | Acute Pancreatitis

United States, India
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Recurrent Genital Herpes
GRI Bio, Inc.

Terminated

Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease (GRI-201)

Chronic Liver Disease

South Africa
United BioPharma
Taipei Veterans General Hospital, Taiwan

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Herpes Simplex Virus Infection

Taiwan
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Bayer

Terminated

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors

Neoplasms

Netherlands
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

CP-461 for the Treatment of Crohn's Disease

Crohn's Disease

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
MyoKardia, Inc.

Completed

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, France, Germany, Czechia, Spain, Belgium, Denmark, Portugal, Netherlands, Israel, Poland, United Kingdom, Italy
MyoKardia, Inc.

Completed

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) (MAVERICK-HCM)

Non-obstructive Hypertrophic Cardiomyopathy

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
United BioPharma
National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaborators

Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

HIV-1 Infection

Taiwan
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

Healthy Volunteers

China
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients (HIV-1)

HIV-1-infection
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension

3

Subscribe